- Page 1: Clinical Study Report A multicentre
- Page 5 and 6: Sponsor: ISU ABXIS Co.,Ltd Study nu
- Page 7 and 8: Sponsor: ISU ABXIS Co.,Ltd Study nu
- Page 9 and 10: Sponsor: ISU ABXIS Co.,Ltd Study nu
- Page 11 and 12: Sponsor: ISU ABXIS Co.,Ltd Study nu
- Page 13 and 14: 9.5.1. Efficacy and safety measurem
- Page 15 and 16: LIST OF IN-TEXT TABLES & FIGURE TAB
- Page 17 and 18: 4. List of abbreviations and defini
- Page 19 and 20: Coordination investigator : Prof. Y
- Page 21 and 22: Abciximab, one of platelet glycopro
- Page 23 and 24: Test items Study flow chart * Women
- Page 25 and 26: (3) Culprit lesion in the bypass gr
- Page 27 and 28: Product Name Clotinab Generic Name
- Page 29 and 30: Biostatisitician Kyoung-A Kim, Byeo
- Page 31 and 32: The primary efficacy endpoint is th
- Page 33 and 34: 9.5.1.2. Safety measurement assesse
- Page 35 and 36: v) None: AE occurs independently fr
- Page 37 and 38: 9.7.1. Statistical and Analytical P
- Page 39 and 40: lood cell (RBC) infused within 48 h
- Page 41 and 42: H0 : p ≥ 0.2 versus HA : p < 0.2
- Page 43 and 44: Table 10.1:1 Disposition of Subject
- Page 45 and 46: Table 10.2:1 Listing of subjects wi
- Page 47 and 48: 1) 2) 3) 4) next 53 patients with r
- Page 49 and 50: Max 77.0 77.0 77.0 Height (cm) N 82
- Page 51 and 52: Table 11.2.1:5 Subject demographics
- Page 53 and 54:
Table 11.2.1:6 Subject demographics
- Page 55 and 56:
Medical history data are summarized
- Page 57 and 58:
Table 11.2.2:3 Pre-trial interview
- Page 59 and 60:
Table 11.2.2:5 Medical History (FAS
- Page 61 and 62:
11.3. Efficacy results, tabulations
- Page 63 and 64:
Angina (%) Table 11.3.1:2 Major Adv
- Page 65 and 66:
Angina (%) Emergency revascularizat
- Page 67 and 68:
Visit 12hr Baseline C.I. : confiden
- Page 69 and 70:
Visit 12hr Baseline Table 11.3.2:4
- Page 71 and 72:
Visit 12hr Table 11.3.2:6 The chang
- Page 73 and 74:
12. Safety evaluation Eighty-three
- Page 75 and 76:
Bleeding Number of Patients Table 1
- Page 77 and 78:
Table 12.2:5 Number of patients wit
- Page 79 and 80:
Hb Hct Table 12.4:1 Hb/Hct - Clotin
- Page 81 and 82:
egion-specific) or C region (consta
- Page 83 and 84:
Clotinab (N=83) ReoPro ® (N=40) Ta
- Page 85 and 86:
Body system Blood and lymphatic sys
- Page 87 and 88:
Body system CSR_Clotinab_II 87 Ver.
- Page 89 and 90:
Table 12.6.2:2 Number observed and
- Page 91 and 92:
Body system CSR_Clotinab_II 91 Ver.
- Page 93 and 94:
The subject Y056 (KMC, male, 57 yea
- Page 95 and 96:
Subject ID Table 12.7:2 Subjects wi
- Page 97 and 98:
12.8. Clinical laboratory evaluatio
- Page 99 and 100:
13. Discussion and overall conclusi
- Page 101 and 102:
The intention of this clinical stud
- Page 103 and 104:
14. Reference list (1) 혈소판
- Page 105 and 106:
(28) Willerson JT, Golino P, Eidt J
- Page 107 and 108:
Table 15. 1 Medication administered
- Page 109 and 110:
Table 15. 2 Concomitant medication
- Page 111 and 112:
Table 15. 3 Medication - administer
- Page 113 and 114:
Table 15. 4 Concomitant medication
- Page 115 and 116:
Table 15. 5 Medication - administer
- Page 117 and 118:
Table 15. 6 Concomitant medication
- Page 119 and 120:
Table 15. 7 Disposition of subjects
- Page 121 and 122:
Table 15. 9 The rate of adverse eve
- Page 123 and 124:
Body system/Preferred term Number o
- Page 125 and 126:
Table 15. 10 Number observed and ra
- Page 127 and 128:
Body system Gastrointestinal disord
- Page 129 and 130:
General disorders and administratio
- Page 131 and 132:
General disorders and administratio
- Page 133 and 134:
Body system Hypoaesthesia 3(3.61%)
- Page 135 and 136:
Body system Vascular disorders Ging
- Page 137 and 138:
Body system Gastrointestinal disord
- Page 139 and 140:
Body system Face oedema 1(2.50%) Y0
- Page 141 and 142:
Body system Psychiatric disorders S
- Page 143 and 144:
Subject list of all adverse events
- Page 145 and 146:
Subject list of all adverse events
- Page 147 and 148:
Subject list of all adverse events
- Page 149 and 150:
Subject list of all adverse events
- Page 151 and 152:
Subject list of all adverse events
- Page 153 and 154:
Subject list of all adverse events
- Page 155 and 156:
Subject list of all adverse events
- Page 157 and 158:
Subject list of all adverse events
- Page 159 and 160:
Subject list of all adverse events
- Page 161 and 162:
Subject list of all adverse events
- Page 163 and 164:
Subject list of all adverse events
- Page 165 and 166:
Subject list of all adverse events
- Page 167 and 168:
Subject list of all adverse events
- Page 169 and 170:
Subject list of all adverse events
- Page 171 and 172:
Subject list of all adverse events
- Page 173 and 174:
Subject list of all adverse events
- Page 175 and 176:
Subject list of all adverse events
- Page 177 and 178:
Subject list of all adverse events
- Page 179 and 180:
Subject list of all adverse events
- Page 181 and 182:
Subject list of all adverse events
- Page 183 and 184:
Table 15. 13 Laboratory Data WBC RB
- Page 185 and 186:
PLT Neutro. (seg) Table 15. 13 Labo
- Page 187 and 188:
Table 15.13 Laboratory Data (Contin
- Page 189 and 190:
Table 15. 13 Laboratory Data (Conti
- Page 191 and 192:
SGOT (AST) SGPT (ALT) Table 15. 13
- Page 193 and 194:
Table 15. 13 Laboratory Data (Conti
- Page 195 and 196:
Table 15. 13 Laboratory Data (Conti
- Page 197 and 198:
Table 15. 14 Cardiac Marker Clotina
- Page 199 and 200:
Table 15. 15 Urinalysis-Clotinab IT
- Page 201 and 202:
Table 15. 16 Urinalysis-ReoPro ® I
- Page 203 and 204:
Table 15. 17 Coagulation ITEM(APTT
- Page 205 and 206:
Table 15. 18 Vital sign (continued)
- Page 207 and 208:
Table 15. 19 Physical examination-C
- Page 209 and 210:
Table 15. 20 Physical examination -
- Page 211 and 212:
Table 15. 21 Listing of subjects wi
- Page 213 and 214:
NO. Subject ID Group Comment 54 Y03
- Page 215:
Deviation type N : no ACT measureme